Clinical Trials Logo

Hyperlipidemia clinical trials

View clinical trials related to Hyperlipidemia.

Filter by:

NCT ID: NCT00231621 Terminated - Obesity Clinical Trials

A Study on Efficacy and Safety of Topiramate in Treatment of Obese Subjects With Dyslipidemia

Start date: May 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of daily topiramate versus placebo for the treatment of obese subjects with dyslipidemia.

NCT ID: NCT00166166 Terminated - Hyperlipidemia Clinical Trials

Endothelial Hyperpolarization in Humans

Start date: July 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to elucidate the role Endothelium-Derived Hyperpolarizing Factor (EDHF) plays in dilating blood vessels and whether it differs between healthy people and those with high cholesterol. A second purpose of the study is to determine the identity of EDHF.

NCT ID: NCT00108485 Terminated - Clinical trials for Diabetes Mellitus, Type 2

Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy

Start date: April 2005
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to test the effectiveness and tolerability of Niaspan® to improve the levels of blood fats ("good" and "bad" cholesterol and triglyceride levels) in people who have kidney damage due to diabetes. A secondary goal is to test whether Niaspan® slows down further development of kidney damage.

NCT ID: NCT00004466 Terminated - Hyperlipidemia Clinical Trials

Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome

Start date: October 1998
Phase: Phase 2
Study type: Interventional

OBJECTIVES: I. Determine the effect of atorvastatin on the plasma levels of lipids, Lp(a), and apoproteins for treating hyperlipidemia in children with nephrotic syndrome in whom proteinuria and hyperlipidemia persist after other appropriate measures to treat their primary disease have been exhausted. II. Determine the safety and tolerability of atorvastatin in these patients. III. Provide preliminary data for a future investigation into the potential effect that lowering cholesterol levels may have on the rate of progression of renal insufficiency in such patients.